Catalyst Wire Dossier Catalyst Wire Dossier

Brimonidine tartrate 0.025% / Ketotifen fumarate 0.035% ophthalmic solution

brimonidine tartrate/ketotifen fumarate ophthalmic solution · Bausch & Lomb Incorporated
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Brimonidine tartrate 0.025% / Ketotifen fumarate 0.035% ophthalmic solution, covering 2025-07-10 to 2025-07-10. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution [Phase 3]

See pricing